At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Move aligns global biologics identity under the Biocon Biologics brand
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Subscribe To Our Newsletter & Stay Updated
